The EU's second-highest court, the General Court of the European Union, ruled partially against the Commission’s decision to ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, both of whom expressed interest in supporting the activist investor's ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

A federal judge ordered the tech giant to let rival app stores onto its Android smartphone platform, adding to its growing ...

Spread the lovePfizer, the pharmaceutical giant, is facing a tough battle to appease its activist investor, Elliott ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...